[Skip to Navigation]
Views 833
Citations 0
Research Letter
January 25, 2021

Diabetic Ketoacidosis at the Time of Diagnosis of Type 1 Diabetes in Children: Insights From TRIGR

Author Affiliations
  • 1Department of Pediatrics, Montreal Children’s Hospital, McGill University, Montreal, Quebec, Canada
  • 2Division of Bioinformatics and Biostatistics Pediatric Epidemiology Center, Department of Pediatrics, University of South Florida, Tampa
  • 3Division of Endocrinology, UPMC Children’s Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 4Department of Pediatrics, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada
  • 5Linköping University Hospital, Linköping, Sweden
  • 6Division of Pediatrics, Department of Clinical and Experimental Medicine, Medical Faculty, Linköping University, Linköping, Sweden
  • 7University of Helsinki, Helsinki, Finland
  • 8Helsinki University Hospital, Helsinki, Finland
JAMA Pediatr. Published online January 25, 2021. doi:10.1001/jamapediatrics.2020.5512

Type 1 diabetes (T1D) is one of the most common chronic diseases of childhood. If left untreated, diabetic ketoacidosis (DKA), a largely preventable life-threatening complication, will occur. Currently, 19% of Canadian children and 40% of US children will present with DKA at the time of diagnosis of T1D.1,2 Because symptoms of T1D exist before the onset of DKA, 1 risk factor for DKA is a delay in the diagnosis and treatment of T1D. Other risk factors include younger age (<5 years) and lower socioeconomic status (SES).1

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words